MedTrace Logo

Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer

NCT03055143 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-07-23

No results posted yet for this study

Summary

This was a randomized, multi centre, open label, two treatment, two period, two sequence, single dose, crossover study, with at least 28 days washout between doses, conducted under fed (normal breakfast) conditions.

Conditions

  • Breast Cancer and Ovarian Cancer

Interventions

DRUG

SPARC-08-038

2 mg/ml intravenous infusion

DRUG

Ref-08-038

2 mg/ml intravenous infusion

Sponsors & Collaborators

  • Sun Pharma Advanced Research Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-03
Primary Completion
2009-11-28
Completion
2009-11-28
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03055143 on ClinicalTrials.gov